Join the 'Leucovorin' group to help and get support from people like you.
Posted 10 Mar 2016 by Drugs.com
THURSDAY, March 10, 2016 – Expensive drugs are being given far more often to elderly patients with advanced colon cancer, but they offer almost no benefit, a new study suggests. "This research found that there is a trend for elderly late-stage colorectal cancer patients to receive newer, more expensive drugs," said lead author Cathy Bradley, associate director for population science research at ...
Posted 1 Dec 2015 by Drugs.com
A low-cost alternative to the infection-fighting drug Daraprim will be available to patients as soon as next week. The price of Daraprim rose 5,000 percent after it was acquired by Turing Pharmaceuticals earlier this year. The drug is used to treat a parasitic infection called toxoplasmosis. On Tuesday, Imprimis Pharmaceuticals announced it found a backer to distribute a $1-per-pill alternative ...
FDA Medwatch Alert: Leucovorin Calcium Injection (Bedford Laboratories): Recall - Visible Particulate Matter
Posted 10 Jul 2012 by Drugs.com
[Posted 07/06/2012] ISSUE: Bedford Laboratories issued a nationwide recall of three lots of Leucovorin Calcium Injection, due to the discovery of visible crystalline particulate matter in a small number of vials. To date, there have been no reports of any adverse events for the lots being recalled. The particulate matter has been identified as active drug substance and not foreign material or ...
Posted 11 May 2011 by Drugs.com
WEDNESDAY, May 11 – A four-drug chemotherapy regimen for deadly pancreatic cancer nearly doubled patients' survival time compared to standard chemotherapy, a new study suggests. In late-stage trials, French researchers split a group of 342 patients with advanced pancreatic adenocarcinoma, the most common form of the disease, into two groups. Half received gemcitabine, the standard treatment, ...
Posted 2 May 2011 by Drugs.com
IRVINE, Calif.--(BUSINESS WIRE)--Apr 30, 2011 - Spectrum Pharmaceuticals a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, received approval from the U.S. Food and Drug Administration (FDA) on April 29, 2011, for the use of Fusilev (levoleucovorin) in combination with 5-fluorouracil in the palliative treatment of patients ...
Ask a Question
Related Condition Support Groups
Colorectal Cancer, Methotrexate Overdosage, Anemia, Megaloblastic, Folic Acid Antagonist Overdose, Methotrexate Rescue, Pneumocystis Pneumonia, Pneumocystis Pneumonia Prophylaxis, Toxoplasmosis, Toxoplasmosis - Prophylaxis